Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-08-09
2011-08-09
Ton, Thaian N (Department: 1632)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S325000
Reexamination Certificate
active
07994298
ABSTRACT:
The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
REFERENCES:
patent: 5359046 (1994-10-01), Capon et al.
patent: 6407319 (2002-06-01), Rose-Fricker et al.
patent: WO02068615 (2002-09-01), None
Wu et al (Science 285: 730-732, 1999).
Heuser et al, Gene Therapy, 10:1408-1419, 2003).
Diefenbach et al (Current Opinion in Immunology, 15(1): 37-44, 2003).
Cambier et al (The Journal of Immunology, 3281-3285, 1995).
Wilson et al (Immunologic Research, 22/1:21-42,2 000).
Rosen et al (J Immunol, 173; 2470-2478, 2004).
Baba et al., “N-Linked Carbohydrate on Human Leukocyte Antigen-C and Recognition by natural Killer Cell Inhibitory Receptors”, Human Immunology 20000 61:1202-1218.
Bonini et al., “HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia”, Science 1997 276:1720-1724.
Clay et al., “Efficient Transfer of a Tumor Antigen-Reactive TCR to Human Peripheral Blood Lymphocytes Confers Anti-Tumor Reactivity”, The Journal of Immunology 1999 163:507-513.
Gonzalez et al., “Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma”, J Gene Med 2004 6:704-711.
Moingeon et al., “Human natural killer cells and mature T lymphocytes express identical CD3 Zeta subunits as defined by cDNA cloning and sequence analysis”, Eur. J. Immunol. 1990 20:1741-1745.
Oelke et al., “Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells”, Nature Medicine 2003 9(5):619-624.
Reilly, R. Todd, “Proper Costimulation of Tumor-Reactive T Lymphocytes May Provide a Key to Unlock Their Antitumor Activity”, Cancer Biology & Therapy 2003 2(5):587-588.
Stancovski et al., “Targeting of T Lymphocytes to Neu/HER2-Expressing Cells Using Chimeric Single Chain Fv Receptors”, J. Immunol 1993 151(11):6577-6582.
Stevens et al., “Generation of Tumor-Specific CTLs from Melanoma Patients by Using Peripheral Blood Stimulated with Allogeneic Melanoma Tumor Cell Lines”, J. Immunol 1995 154:762-771.
Thomis et al., “A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease”, Blood 2001 97(5):1249-1257.
Zhang et al., “Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy”, Blood 2005 106(5):1544-1551.
NCBI Accession No. NM—002262 [gi:7669497] with Revision History—Feb. 5, 2006—Nov. 17, 2006.
NCBI Accession No. NM—007334 [gi:7669498] with Revision History—Feb. 5, 2006—Nov. 17, 2006.
NCBI Accession No. NM—002543 [gi:37595562] with Revision History—Aug. 13, 2006—Feb. 18, 2007.
NCBI Accession No. AF461811 [gi:18182679] Jan. 17, 2002.
NCBi Accession No. AJ312373 [gi:14599393] with Revision History—Jul. 3, 2001-Apr. 15, 2005.
NCBI Accession No. NM—001781 [gi: 4502680] with Revision History—Mar. 30, 2006-Nov. 17, 2006.
NCBI Accession No. U11276 [gi:538270] with Revision History-Sep. 16, 1994-Sep. 23. 1994.
NCBI Accession No. AF098358 [gi:4139191].
NCBI Accession No. AF133299 [gi:6651064].
NCBI Accession No. NM—016509 with Revision History—Mar. 2, 2006-Nov. 18, 2006.
NCBI Accession No. BC-30937 {gi:24980984] with Revision History—Jun. 25, 2004-Jul. 15, 2006.
NCBI Accession No. AF072845 [gi:5690195].
NCBI Accession No. AF461157 [gi:18182677].
NCBI Accession No. AF461812 [gi:18182681].
NCBI Accession No. NM—198053 [gi:37595564] with Revision History—Oct. 15, 2006-Jan. 14, 2007.
NCBI Accession No. AJ271694 [gi:6900101] with Revision History—Feb. 2, 2000-Nov. 14, 2006.
NCBI Accession No. AJ001383 [gi:3647278] with Revision History—Sep. 22, 1998.
NCBI Accession No. AB055881 [gi:17221621] with Revision History—Dec. 1, 2001.
NCBI Accession No. AJ225109 [gi:4493701] with Revision History—Mar. 15, 1999.
NCBI Accession No. AF019562 [gi:2905993] with Revision History—Jan. 26, 1999.
NCBI Accession No. M33195 [gi:182487] with Revision History—Oct. 2, 1992-Apr. 27, 1993.
NCBI Accession No. NM—016523 [gi:7705573] with Revision History—Apr. 22, 2005-Feb. 27, 2007.
NCBI Accession No. AJ001684 [gi:2980858] with Revision History—Sep. 4, 1998-Nov. 14, 2006.
NCBI Accession No. NM—001782 [gi:4502682] with Revision History—Aug. 13, 2006-Mar. 11, 2007.
Wu et al., An activating immunoreceptor complex formed by NKG2D and DAP10, Science, 285: 730-732, 1999.
Heuser et al., T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T-cells, Gene Therapy 10: 1408-1419, 2003.
Diefenbach et al., Innate immune recognition by stimulatory immunoreceptors, Current Opinion in Immunology, 15(1): 37-44, 2003.
Belakova et al., DNA vaccines: are they still just a powerful tool for the future? Arch Immunol Ther Exp. (Warsz), 55(6): 387-398, 2007.
Mittendorf et al., Breast cancer vaccines: promise for the future or pipe dream? Cancer, 110(8): 1677-1686, 2007.
Ulmer et al., Gene-based vaccines: recent technical and clinical advances. Trends Mol Med. 12(5): 216-222, 2006.
Diefenbach et al., The innate immune response to tumors and its role in the induction of T-cell immunity, Immunol Rev. 188: 9-21, 2002.
Gilham et al., Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors, J. Immunother, Mar.-Apr. 2002: 25(2): 139-151, 2002.
Lowin-Kropf et al., Cytoskeletal polarization of T cells is regulated by an immunoreceptor tyrosine-based activation motif-dependent mechanism, J Cell Biol. 140(40: 861-871, 1998.
Bauer et al., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA, Science 285(5428): 727-729, 1999.
Houchins et al., DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer Glees, J Exp. Med. 173(4): 1017-1020, 1991.
Sentman Charles L.
Zhang Tong
Hunton & Williams LLP
Sgagias Magdalene
Ton Thaian N
Trustees of Dartmouth College
LandOfFree
Chimeric NK receptor and methods for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric NK receptor and methods for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric NK receptor and methods for treating cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2751124